The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the underwriters in connection with the $500 million public offering by Beam Therapeutics Inc. of 16,151,686 SEC-registered shares of common stock and SEC-registered pre-funded warrants to purchase 1,404,988 shares of common stock. The common stock is listed on the Nasdaq Global Select Market under the symbol “BEAM.”

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

The Davis Polk corporate team included partners Yasin Keshvargar and Deanna L. Kirkpatrick and associates Xi (Brooke) Zheng and Juan Diego Tibaduiza. Partner David R. Bauer and associate Jordan Khorshad provided intellectual property advice. The tax team included partner Mario J. Verdolini and associate Charlotte Bilski Matthews. All members of the Davis Polk team are based in the New York office.

Copy link to share post